CDKN2B-AS1 and psoriasis: Several lncRNAs might act as psoriasis biomarkers and/or therapy targets, such as the IL−22-responsive SPRR2C [37], psoriasis susceptibility gene PRINS [39,40], NF-κB-dependent ANRIL [61], IL−17A-promoting H19 [51], and the innate immune response-related HOTAIR [70] and MALAT1 [44,45,71].